Emerging treatment options for skin and soft tissue infections tailoring drug selection to individual patients.
Journal
Current opinion in infectious diseases
ISSN: 1473-6527
Titre abrégé: Curr Opin Infect Dis
Pays: United States
ID NLM: 8809878
Informations de publication
Date de publication:
25 Jan 2024
25 Jan 2024
Historique:
medline:
26
1
2024
pubmed:
26
1
2024
entrez:
26
1
2024
Statut:
aheadofprint
Résumé
To provide a brief overview of drugs in Phase II and III of development for the treatment of acute bacterial skin and skin structure infections (ABSSSI), offering insights into potential customized treatment options. Several drugs are currently in advanced stages of evaluation for the treatment of ABSSSI, and numerous molecules are entering in the early development phases. Notably, many of these drugs exhibit unique mechanisms of action and interesting antimicrobial spectrum. Tailoring antibiotic therapy based on patient characteristics, likely pathogens, type, site and severity of ABSSSI is crucial. Given the inherent limitations of available treatments, the development of novel agents is a pivotal avenue. Such advancements hold promise for enhancing treatment efficacy and simplifying drug selection for ABSSSI in everyday clinical practice.
Identifiants
pubmed: 38277175
doi: 10.1097/QCO.0000000000001003
pii: 00001432-990000000-00134
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Hersh AL, Chambers HF, Maselli JH, et al. National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections. Arch Intern Med 2008; 168:1585–1591.
Miller LG, Eisenberg DF, Liu H, et al. Incidence of skin and soft tissue infections in ambulatory and inpatient settings, 2005–2010. BMC Infect Dis 2015; 15:362.
Lipsky BA, Napolitano LM, Moran GJ, et al. Economic outcomes of inappropriate initial antibiotic treatment for complicated skin and soft tissue infections: a multicenter prospective observational study. Diagn Microbiol Infect Dis 2014; 79:266–272.
Berger A, Oster G, Edelsberg J, et al. Initial treatment failure in patients with complicated skin and skin structure infections. Surg Infect (Larchmt) 2013; 14:304–312.
Ruhe JJ, Smith N, Bradsher RW, et al. Community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome. Clin Infect Dis 2007; 44:777–784.
Bassetti M, Baguneid M, Bouza E, et al. European perspective and update on the management of complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid. Clin Microbiol Infect 2014; 20: (Suppl 4): 3–18.
Russo A, Vena A, Bassetti M. Antibiotic treatment of acute bacterial skin and skin structure infections. Curr Opin Infect Dis 2022; 35:120–127.
Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 2014; 59:e10–e52.
Jaffa RK, Pillinger KE, Roshdy D, et al. Novel developments in the treatment of acute bacterial skin and skin structure infections. Expert Opin Pharmacother 2019; 20:1493–1502.
Bassetti M, Peghin M, Castaldo N, et al. The safety of treatment options for acute bacterial skin and skin structure infections. Expert Opin Drug Saf 2019; 18:635–650.
Bassetti M, Magnasco L, Del Puente F, et al. Role of new antibiotics in the treatment of acute bacterial skin and skin-structure infections. Curr Opin Infect Dis 2020; 33:110–120.
Giacobbe DR, Labate L, Vena A, et al. Potential role of new-generation antibiotics in acute bacterial skin and skin structure infections. Curr Opin Infect Dis 2021; 34:109–117.
Bassetti M, Pecori D, Cojutti P, et al. Clinical and pharmacokinetic drug evaluation of delafloxacin for the treatment of acute bacterial skin and skin structure infections. Expert Opin Drug Metab Toxicol 2017; 13:1193–1200.
Giacobbe DR, Dettori S, Corcione S, et al. Emerging treatment options for acute bacterial skin and skin structure infections and bloodstream infections caused by staphylococcus aureus: a comprehensive review of the evidence. Infect Drug Resist 2022; 15:2137–2157.
Bassetti M, Peghin M, Carnelutti A, et al. The role of dalbavancin in skin and soft tissue infections. Curr Opin Infect Dis 2018; 31:141–147.
Lemaire S, Kosowska-Shick K, Appelbaum PC, et al. Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila. Antimicrob Agents Chemother 2010; 54:2549–2559.
Wang L, Zhang Y, Liu S, et al. Comparison of anti-microbic and anti-biofilm activity among tedizolid and radezolid against linezolid-resistant enterococcus faecalis isolates. Infect Drug Resist 2021; 14:4619–4627.
NCT00646958. Safety and efficacy study of oxazolidinones to treat uncomplicated skin infections. 2014: Available at: https://clinicaltrials.gov/ct2/show/results/NCT00646958.
Li CR, Zhai QQ, Wang XK, et al. In vivo antibacterial activity of MRX-I, a new oxazolidinone. Antimicrob Agents Chemother 2014; 58:2418–2421.
Zhao X, Huang H, Yuan H, et al. A Phase III multicentre, randomized, double-blind trial to evaluate the efficacy and safety of oral contezolid versus linezolid in adults with complicated skin and soft tissue infections. J Antimicrob Chemother 2022; 77:1762–1769.
Hoy SM. Contezolid: first approval. Drugs 2021; 81:1587–1591.
Bassetti M, Del Puente F, Magnasco L, et al. Innovative therapies for acute bacterial skin and skin-structure infections (ABSSSI) caused by methicillin-resistant Staphylococcus aureus: advances in phase I and II trials. Expert Opin Investig Drugs 2020; 29:495–506.
Kowalski RP, Romanowski EG, Yates KA, et al. An independent evaluation of a novel peptide mimetic, brilacidin (PMX30063), for ocular antiinfective. J Ocul Pharmacol Ther 2016; 32:23–27.
Xu C, Wang A, Honnen W, et al. Brilacidin, a non-peptide defensin-mimetic molecule, inhibits SARS-CoV-2 infection by blocking viral entry. EC Microbiol 2022; 18:1–12.
PolyMedix. PolyMedix announces positive results from phase 2 clinical trial with PMX-30063 first-in-class defensin-mimetic antibiotic. Available at: http://www.globenewswire.com/news-release/2012/04/23/473929/252858/en/PolyMedix-Announces-Positive-Results-From-Phase-2-Clinical-Trial-With-PMX-30063-First-in-Class-Defensin-Mimetic-Antibiotic.html.
NCT02052388. Efficacy and safety study of brilacidin to treat serious skin infections. 2018.
Jorgensen D SR, O’Riordan W, Tack K. A randomized, double-blind study comparing single-dose and short-course brilacidin to daptomycin in the treatment of acute bacterial skin & skin structure infections (ABSSSI) [abstract 2969]. ECCMID; Copenhagen, Denmark, April 25−28 2015.
Huang DB, File TM Jr, Dryden M, et al. Surveillance of iclaprim activity: In vitro susceptibility of gram-positive pathogens collected from 2012 to 2014 from the United States, Asia Pacific, Latin American and Europe. Diagn Microbiol Infect Dis 2018; 90:329–334.
Kohlhoff SA, Sharma R. Iclaprim. Expert Opin Investig Drugs 2007; 16:1441–1448.
Huang DB, Dryden M. Iclaprim, a dihydrofolate reductase inhibitor antibiotic in Phase III of clinical development: a review of its pharmacology, microbiology and clinical efficacy and safety. Future Microbiol 2018; 13:957–969.
Huang DB, O’Riordan W, Overcash JS, et al. A Phase 3, randomized, double-blind, multicenter study to evaluate the safety and efficacy of intravenous iclaprim vs vancomycin for the treatment of acute bacterial skin and skin structure infections suspected or confirmed to be due to gram-positive pathogens: REVIVE-1. Clin Infect Dis 2018; 66:1222–1229.
Holland TL, O’Riordan W, McManus A, et al. A Phase 3, randomized, double-blind, multicenter study to evaluate the safety and efficacy of intravenous iclaprim versus vancomycin for treatment of acute bacterial skin and skin structure infections suspected or confirmed to be due to gram-positive pathogens (REVIVE-2 Study). Antimicrob Agents Chemother 2018; 62:e02580–17.
Huang DB, Corey GR, Holland TL, et al. Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections. Int J Antimicrob Agents 2018; 52:233–240.
plc. M. MotifBio receives complete response letter from the FDA 2019. Available at: https://www.motifbio.com/news/motif-bio-receivescomplete-response-letter-from-the-fda/pp.
Veve MP, Wagner JL. Lefamulin: review of a promising novel pleuromutilin antibiotic. Pharmacotherapy 2018; 38:935–946.
Paukner S, Gelone SP, Arends SJR, et al. Antibacterial activity of lefamulin against pathogens most commonly causing community-acquired bacterial pneumonia: SENTRY Antimicrobial Surveillance Program (2015−2016). Antimicrob Agents Chemother 2019; 63:e02161-18.
Bassetti M, Labate L, Melchio M, et al. Current pharmacotherapy for methicillin-resistant Staphylococcus aureus (MRSA) pneumonia. Expert Opin Pharmacother 2022; 23:361–375.
Prince WT, Ivezic-Schoenfeld Z, Lell C, et al. Phase II clinical study of BC-3781, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections. Antimicrob Agents Chemother 2013; 57:2087–2094.
Wittke F, Vincent C, Chen J, et al. Afabicin, a first-in-class antistaphylococcal antibiotic, in the treatment of acute bacterial skin and skin structure infections: clinical noninferiority to vancomycin/linezolid. Antimicrob Agents Chemother 2020; 64:e00250-20.
Park HS, Yoon YM, Jung SJ, et al. Antistaphylococcal activities of CG400549, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor. J Antimicrob Chemother 2007; 60:568–574.
CrystalGenomics I. CrystalGenomics reports positive top-line data from phase 2a study of CG400549 in patients with complicated acute bacterial skin and skin structure infections caused by MRSA. Available at: https://www.prnewswire.com/news-releases/crystalgenomics reports- positive-top-line-data-from-phase-2a-study-of-cg400549-in-patients-with-complicated-acute-bacterialskin-and-skin-structure-infections-caused-by-mrsa-185870042.html.pp.
Reviews KB. Crystal genomics confirms safety of super bacteria antibiotic candidate. 2020: Available at: http://www.koreabiomed.com/news/articleView.html?idxno=8709.
Tellis M, Joseph J, Khande H, et al. In vitro bactericidal activity of levonadifloxacin (WCK 771) against methicillin- and quinolone-resistant Staphylococcus aureus biofilms. J Med Microbiol 2019; 68:1129–1136.
Bhatia A, Mastim M, Shah M, et al. Efficacy and safety of a novel broad-spectrum anti-MRSA agent levonadifloxacin compared with linezolid for acute bacterial skin and skin structure infections: a phase 3, Openlabel, Randomized Study. J Assoc Physicians India 2020; 68:30–36.
Limited W. India's first new discovery antibiotics from Wockhardt Granted Indian Regulatory Approval. Available at: https://www.wockhardt.com/investor/indias-first-new-discovery-antibiotics-from-wockhardt-granted-indian-regulatory-approval/pp.
Jones TM, Johnson SW, DiMondi VP, et al. Focus on JNJ-Q2, a novel fluoroquinolone, for the management of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Infect Drug Resist 2016; 9:119–128.
Covington P, Davenport JM, Andrae D, et al. Randomized, double-blind, phase II, multicenter study evaluating the safety/tolerability and efficacy of JNJ-Q2, a novel fluoroquinolone, compared with linezolid for treatment of acute bacterial skin and skin structure infection. Antimicrob Agents Chemother 2011; 55:5790–5797.
Eichenbaum G, Pugsley MK, Gallacher DJ, et al. Role of mixed ion channel effects in the cardiovascular safety assessment of the novel anti-MRSA fluoroquinolone JNJ-Q2. Br J Pharmacol 2012; 166:1694–1707.
Flamm RK, Farrell DJ, Rhomberg PR, et al. Gepotidacin (GSK2140944) in vitro activity against gram-positive and gram-negative bacteria. Antimicrob Agents Chemother 2017; 61:e00468–17.
O’Riordan W, Tiffany C, Scangarella-Oman N, et al. Efficacy, safety, and tolerability of gepotidacin (GSK2140944) in the treatment of patients with suspected or confirmed gram-positive acute bacterial skin and skin structure infections. Antimicrob Agents Chemother 2017; 61:e02095–16.
Surur AS, Sun D. Macrocycle-antibiotic hybrids: a path to clinical candidates. Front Chem 2021; 9:659845.
Ma Z, Lynch AS. Development of a dual-acting antibacterial agent (TNP-2092) for the treatment of persistent bacterial infections. J Med Chem 2016; 59:6645–6657.
Koh AJJ, Thombare V, Hussein M, et al. Bifunctional antibiotic hybrids: a review of clinical candidates. Front Pharmacol 2023; 14:1158152.
Therapeutics T. TenNor therapeutics reported phase II top-line results for TNP-2092 2019. Available at https://www.prnewswire.com/news-releases/tennor-therapeutics-reported-phase-ii-top-line-results-for-tnp-2092-300955216.html. [Accessed 16 January 2023]
Blais J, Lewis SR, Krause KM, et al. Antistaphylococcal activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic. Antimicrob Agents Chemother 2012; 56:1584–1587.
Stryjewski ME, Potgieter PD, Li YP, et al. TD-1792 versus vancomycin for treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 2012; 56:5476–5483.
Douglas EJA, Laabei M. Staph wars: the antibiotic pipeline strikes back. Microbiology (Reading) 2023; 169:001387.